EADV 2026 Highlights: Key Psoriasis Findings Unveiled
A comprehensive overview of the most significant psoriasis research presented at the EADV 2026 Congress.
New data reveals over 70% of patients achieved significant psoriasis clearance with icotrokinra.
Ixekizumab combined with tirzepatide shows enhanced biomarker effects in psoriasis treatment.
The EADV 2026 Congress showcased advancements in psoriasis management and treatment options.
The 2026 European Academy of Dermatology and Venereology (EADV) Congress has concluded, presenting groundbreaking research on psoriasis and related skin conditions. Key findings from the event include the efficacy of new treatments and their implications for patient care. This year's congress took place in Vienna, attracting dermatology experts from around the globe to share insights and advancements in the field.
Among the most notable presentations was the two-year data from the ICONIC-LEAD trial, which demonstrated that oral icotrokinra maintained a PASI 90 response in over 70% of adults and adolescents suffering from plaque psoriasis. This significant result underscores the potential of icotrokinra as a long-term treatment option for patients, offering hope for improved management of this chronic condition.
Additionally, the TOGETHER-PsO study revealed that the combination of ixekizumab and tirzepatide resulted in broader immune and metabolic changes compared to ixekizumab alone. This finding suggests that combining therapies may enhance treatment outcomes for patients with both psoriasis and obesity, highlighting the interconnectedness of these conditions.
The implications of these findings extend beyond individual patient care, potentially influencing treatment protocols and guidelines within the dermatology community. As psoriasis affects millions worldwide, advancements presented at EADV 2026 could lead to more effective management strategies, improving the quality of life for many.
Looking ahead, researchers and clinicians will continue to monitor the long-term effects of these treatments. Future studies are expected to delve deeper into the mechanisms of action and the overall impact of these therapies on patient health. The next EADV Congress promises to build on this year's successes, further advancing the field of dermatology and psoriasis treatment.
